Rubicon Antibody: ATTO 594

Rubicon (RUN domain Beclin-1-interacting and cysteine-rich-containing protein) is a negative regulator of autophagy, a cellular degradation pathway essential for maintaining neuronal homeostasis. As neurons are particularly vulnerable to the accumulation of damaged proteins and organelles, dysregulation of autophagy is a hallmark of many neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS. Rubicon inhibits autophagosome maturation by interacting with components of the PI3K complex and RAB7A, thereby blocking lysosomal fusion. In the aging brain, elevated Rubicon levels have been associated with impaired autophagic flux and increased vulnerability to proteotoxic stress 1. Notably, Rubicon expression is upregulated in Alzheimer’s disease, where it contributes to amyloid precursor protein (APP) and amyloid-β (Aβ) accumulation. Neuronal overexpression of Rubicon suppresses Aβ clearance, while its knockdown enhances autophagic degradation and reduces extracellular Aβ deposition (1) . Recent findings also highlight Rubicon’s role in mitophagy regulation. Phosphorylation of RAB7A at Ser72 disrupts its interaction with Rubicon, relieving autophagy inhibition and promoting mitochondrial quality control 2. This phospho-switch mechanism underscores Rubicon’s dynamic regulation in response to cellular stress. Given its central role in autophagy suppression and protein aggregation, Rubicon is a promising therapeutic target. Strategies aimed at modulating Rubicon expression or disrupting its inhibitory interactions may restore autophagic balance and mitigate neurodegenerative progression.

Run domain Beclin-1-interacting and cysteine-rich domain-containing protein, KIAA0226, Rubicon, Baron, RUBCN, Beclin-1 associated RUN domain containing protein

A 1:1000 dilution of SPC-668 was sufficient for detection of Rubicon in 15 µg of human Hela cell lysates by ECL immunoblot analysis using goat anti-rabbit IgG:HRP as the secondary antibody.